During the past decade, Duke University Health Systems conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 7 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 3 clinical trials were completed. i.e. 18.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Duke University Health Systems" #1 sponsor was "Duke University" with 13 trials, followed by "David Rizzieri, MD" with 3 trials sponsored, "Mallinckrodt" with 3 trials sponsored, "Actelion" with 2 trials sponsored and "Case Western Reserve University" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Duke University Health Systems" #1 collaborator was "Duke University" with 5 trials as a collaborator, "Emory University" with 2 trials as a collaborator, "Grady Health System" with 2 trials as a collaborator, "Miltenyi Biomedicine GmbH" with 2 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 34 trials.

According to Clinical.Site data, the most researched conditions in "Duke University Health Systems" are "Lymphoma" (3 trials), "Acute Pain" (2 trials), "Critical Illness" (2 trials), "Hypertension" (2 trials) and "Leukemia" (2 trials). Many other conditions were trialed in "Duke University Health Systems" in a lesser frequency.

Most popular intervention types in "Duke University Health Systems" are "Drug" (19 trials), "Other" (8 trials), "Behavioral" (6 trials), "Device" (6 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Campath Purged Non-myeloablative ASCT" (2 trials), "Advance Care Planning (ACP) Decisions Videos Decisions Aids" (1 trials), "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody" (1 trials), "Azacitidine" (1 trials) and "Blue Light" (1 trials). Other intervention names were less common.

The vast majority of trials in "Duke University Health Systems" are 42 trials for "All" genders.

Currently, there are NaN active trials in "Duke University Health Systems". undefined are not yet recruiting, 11 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 18 completed trials in Duke University Health Systems, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Duke University Health Systems, 8 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 14 trials that are defined as “Not Applicable".